Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) E10: ₹3.52 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:JAGSNPHARM Jagsonpal Pharmaceuticals Ltd NSE:JAGSNPHARM
81 GF Score
Price ₹233.53
GF Value ₹219.46
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Jagsonpal Pharmaceuticals E10?

Jagsonpal Pharmaceuticals NSE:JAGSNPHARM -1.51% 81 E10 is ₹3.52 as of Jun. 2026. GuruFocus rates NSE:JAGSNPHARM with a GF Score™ of 81/100 and a GF Value™ of ₹219.46 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Jagsonpal Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was ₹1.980. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹3.52 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Jagsonpal Pharmaceuticals's average E10 Growth Rate was 25.40% per year. During the past 3 years, the average E10 Growth Rate was 30.70% per year. During the past 5 years, the average E10 Growth Rate was 30.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Jagsonpal Pharmaceuticals was 34.60% per year. The lowest was 25.10% per year. And the median was 30.70% per year.

As of today (2026-08-17), Jagsonpal Pharmaceuticals's current stock price is ₹233.53. Jagsonpal Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 was ₹3.52. Jagsonpal Pharmaceuticals's Shiller PE Ratio of today is 66.34.

During the past 13 years, the highest Shiller PE Ratio of Jagsonpal Pharmaceuticals was 148.51. The lowest was 19.49. And the median was 80.29.


Jagsonpal Pharmaceuticals  (NSE:JAGSNPHARM) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Jagsonpal Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=233.53/3.52
=66.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Jagsonpal Pharmaceuticals was 148.51. The lowest was 19.49. And the median was 80.29.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Jagsonpal Pharmaceuticals E10 Related Terms


Jagsonpal Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Jagsonpal Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jagsonpal Pharmaceuticals E10 Chart

Jagsonpal Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.07 1.47 1.76 2.63 3.27

Jagsonpal Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.79 3.01 3.18 3.27 3.52

NSE:JAGSNPHARM vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jagsonpal Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jagsonpal Pharmaceuticals Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jagsonpal Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Jagsonpal Pharmaceuticals's Shiller PE Ratio falls into.


NSE:JAGSNPHARM
81GF Score
Jagsonpal Pharmaceuticals Ltd NSE:JAGSNPHARM
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jagsonpal Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Jagsonpal Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.98/167.3573*167.3573
=1.980

Current CPI (Jun. 2026) = 167.3573.

Jagsonpal Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201609 0.076 105.961 0.120
201612 1.512 105.196 2.405
201703 0.124 105.196 0.197
201706 -0.644 107.109 -1.006
201709 -0.588 109.021 -0.903
201712 -0.344 109.404 -0.526
201803 -0.188 109.786 -0.287
201806 0.112 111.317 0.168
201809 0.272 115.142 0.395
201812 0.268 115.142 0.390
201903 0.452 118.202 0.640
201906 0.304 120.880 0.421
201909 0.308 123.175 0.418
201912 0.348 126.235 0.461
202003 0.236 124.705 0.317
202006 0.384 127.000 0.506
202009 0.612 130.118 0.787
202012 0.828 130.889 1.059
202103 0.776 131.771 0.986
202106 1.044 134.084 1.303
202109 1.004 135.847 1.237
202112 0.808 138.161 0.979
202203 0.064 138.822 0.077
202206 0.448 142.347 0.527
202209 1.588 144.661 1.837
202212 1.188 145.763 1.364
202303 0.856 146.865 0.975
202306 1.140 150.280 1.270
202309 1.136 151.492 1.255
202312 0.236 152.924 0.258
202403 0.537 153.035 0.587
202406 0.770 155.789 0.827
202409 1.580 157.882 1.675
202412 4.740 158.323 5.010
202503 0.980 157.552 1.041
202506 1.580 159.755 1.655
202509 1.870 162.289 1.928
202512 1.650 163.281 1.691
202603 1.210 164.272 1.233
202606 1.980 167.357 1.980

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹3.52 mean?
Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) has a E10 of ₹3.52 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Jagsonpal Pharmaceuticals and its competitors.
Is Jagsonpal Pharmaceuticals' E10 too high?
Jagsonpal Pharmaceuticals' current E10 is ₹3.52. Overall, Jagsonpal Pharmaceuticals has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jagsonpal Pharmaceuticals' E10 compare to ZTS?
Jagsonpal Pharmaceuticals' E10 of ₹3.52 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Jagsonpal Pharmaceuticals and its competitors. Jagsonpal Pharmaceuticals's current E10 is ₹3.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jagsonpal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹219.46, compared to a current price of ₹233.53 — trading 6.4% above its estimated fair value. The current E10 is ₹3.52. Jagsonpal Pharmaceuticals' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM), the current E10 is ₹3.52 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Jagsonpal Pharmaceuticals stock appears to be overvalued. The current stock price of ₹233.53 is trading 6.4% above its estimated GF Value™ of ₹219.46. GuruFocus considers Jagsonpal Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:JAGSNPHARM:

  • E10: ₹3.52
  • GF Value™: ₹219.46 vs. price of ₹233.53 (6.4% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the NSE:JAGSNPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jagsonpal Pharmaceuticals Business Description

Other Exchanges 507789:India
Address 3rd Floor, Phase - IV, Udyog Vihar, Plot No. 412-415, Nimai Tower, Gurugram, HR, IND, 122015
Jagsonpal Pharmaceuticals Ltd is a pharmaceutical company. It develops and manufactures active pharmaceutical ingredients and formulations like Capsule and Tablet. The company operates in the Gynaecology, Orthopaedics, Dermatology and Paediatric segments. Its brands comprise Lycored, Maintane, Doxypal DR, and others.
81GF Score

Get the complete analysis for NSE:JAGSNPHARM

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹233.53
Price
₹219.46
GF Value